FLT3-TKD mutations have been evaluated as a prognostic factor in AML; some reports have shown that FLT3-TKD mutations are associated with shorter remission and OS, while others have shown that FLT3-TKD mutations do not affect prognosis or display a favorable prognosis [31,32,33]. This evidence concerns the gene FLT3 and acute myeloid leukemia.